Background The Xpert MTB/RIF test enables rapid detection of tuberculosis (TB) and
rifampicin resistance. The World Health Organization recommends Xpert for initial diagnosis …

Background Xpert MTB/RIF (Xpert) is a promising new rapid diagnostic technology for
tuberculosis (TB) that has characteristics that suggest large-scale roll-out. However …

Background Several promising new diagnostic methods and algorithms for tuberculosis
have been endorsed by WHO. National tuberculosis programmes now face the decision on …

Background In 2010 a new diagnostic test for tuberculosis, Xpert MTB/RIF, received a
conditional programmatic recommendation from WHO. Several model-based economic …

Background: In settings with high tuberculosis (TB) prevalence, 15–30% of HIV-infected
individuals initiating antiretroviral therapy (ART) have undiagnosed TB. Such patients are …

Background High costs are a limitation to scaling up the Xpert MTB/RIF assay (Xpert) for the
diagnosis of tuberculosis in resource-constrained settings. A triaging strategy in which a …

Xpert MTB/RIF is a rapid test to diagnose tuberculosis (TB) and rifampicin-resistant TB. Cost
and affordability will influence its uptake. We assessed the cost, globally and in 36 high …

SETTING: Initial cost-effectiveness evaluations of Xpert® MTB/RIF for tuberculosis (TB)
diagnosis have not fully accounted for the realities of implementation in peripheral settings …

Background The Xpert MTB/RIF (Xpert) assay offers rapid and accurate diagnosis of
tuberculosis (TB) but still suffers from imperfect sensitivity. The newer Xpert MTB/RIF Ultra …

Abstract Background. The effect of Xpert MTB/RIF (Xpert) scale-up on patient outcomes in
low-income settings with a high tuberculosis (TB) burden has not been established. We …